EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids

Cynthia Gyamfi-Bannerman, Rebecca G Clifton, Alan T N Tita, Sean C Blackwell, Monica Longo, Jessica A de Voest, T Michael O'Shea, Sabine Z Bousleiman, Felecia Ortiz, Dwight J Rouse, Torri D Metz, George R Saade und 9 weitere

JAMA · 2024

DOI: 10.1001/jama.2024.4303 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA, 2024. Verfasst von Cynthia Gyamfi-Bannerman und 20 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University, New York, New York. Hauptthemen laut MEDLINE: Betamethasone, Glucocorticoids, Neurodevelopmental Disorders, Prenatal Exposure Delayed Effects. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The Antenatal Late Preterm Steroids (ALPS) trial changed clinical practice in the United States by finding that antenatal betamethasone at 34 to 36 weeks decreased short-term neonatal respiratory morbidity. However, the trial also found increased risk of neonatal hypoglycemia after betamethasone. This follow-up study focused on long-term neurodevelopmental outcomes after late preterm steroids.

Objective

To evaluate whether administration of late preterm (34-36 completed weeks) corticosteroids affected childhood neurodevelopmental outcomes. Design, Setting, and Participants Prospective follow-up study of children aged 6 years or older whose birthing parent had enrolled in the multicenter randomized clinical trial, conducted at 13 centers that participated in the Maternal-Fetal Medicine Units (MFMU) Network cycle from 2011-2016. Follow-up was from 2017-2022. Exposure Twelve milligrams of intramuscular betamethasone administered twice 24 hours apart. Main Outcome and Measures The primary outcome of this follow-up study was a General Conceptual Ability score less than 85 (−1 SD) on the Differential Ability Scales, 2nd Edition (DAS-II). Secondary outcomes included the Gross Motor Function Classification System level and Social Responsiveness Scale and Child Behavior Checklist scores. Multivariable analyses adjusted for prespecified variables known to be associated with the primary outcome. Sensitivity analyses used inverse probability weighting and also modeled the outcome for those lost to follow-up.

Results

Of 2831 children, 1026 enrolled and 949 (479 betamethasone, 470 placebo) completed the DAS-II at a median age of 7 years (IQR, 6.6-7.6 years). Maternal, neonatal, and childhood characteristics were similar between groups except that neonatal hypoglycemia was more common in the betamethasone group. There were no differences in the primary outcome, a general conceptual ability score less than 85, which occurred in 82 (17.1%) of the betamethasone vs 87 (18.5%) of the placebo group (adjusted relative risk, 0.94; 95% CI, 0.73-1.22). No differences in secondary outcomes were observed. Sensitivity analyses using inverse probability weighting or assigning outcomes to children lost to follow-up also found no differences between groups. Conclusion and Relevance In this follow-up study of a randomized clinical trial, administration of antenatal corticosteroids to persons at risk of late preterm delivery, originally shown to improve short-term neonatal respiratory outcomes but with an increased rate of hypoglycemia, was not associated with adverse childhood neurodevelopmental outcomes at age 6 years or older.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BetamethasoneGlucocorticoidsNeurodevelopmental DisordersPrenatal Exposure Delayed EffectsChildFemaleHumansInfant, NewbornMalePregnancyChild DevelopmentFollow-Up StudiesInfant, PrematurePremature BirthPrenatal CareProspective Studies

Substanzen

BetamethasoneGlucocorticoids

Autor:innen und Institutionen

  • Columbia University, New York, New York.
  • University of California, San Diego, La Jolla.
  • George Washington University Biostatistics Center, Washington, DC.
  • University of Alabama at Birmingham.
  • University of Texas Health Science Center at Houston-Children's Memorial Hermann Hospital, Houston.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.

Förderung

  • NICHD NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Gyamfi-Bannerman, C., Clifton, R. G., Tita, A. T. N., Blackwell, S. C., Longo, M., de Voest, J. A., O'Shea, T. M., Bousleiman, S. Z., Ortiz, F., Rouse, D. J., Metz, T. D., Saade, G. R., Rood, K. M., Heyborne, K. D., Thorp, J. M., Swamy, G. K., Grobman, W. A., Gibson, K. S., El-Sayed, Y. Y., …, & Eunice Kennedy Shriver Maternal-Fetal Medicine Units Network (2024). Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids. JAMA. https://doi.org/10.1001/jama.2024.4303

Vancouver

Gyamfi-Bannerman C, Clifton RG, Tita ATN, Blackwell SC, Longo M, de Voest JA, et al. Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids. JAMA. 2024. doi:10.1001/jama.2024.4303

BibTeX
@article{GyamfiBannerman2024,
  author = {Gyamfi-Bannerman, Cynthia and Clifton, Rebecca G and Tita, Alan T N and Blackwell, Sean C and Longo, Monica and de Voest, Jessica A and O'Shea, T Michael and Bousleiman, Sabine Z and Ortiz, Felecia and Rouse, Dwight J and Metz, Torri D and Saade, George R and Rood, Kara M and Heyborne, Kent D and Thorp, John M and Swamy, Geeta K and Grobman, William A and Gibson, Kelly S and El-Sayed, Yasser Y and Macones, George A and Eunice Kennedy Shriver Maternal-Fetal Medicine Units Network, Eunice Kennedy Shriver Maternal-Fetal Medicine Units Network},
  title = {Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.4303}
}
Kostenlos starten →